Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Warfarin for Post Cardiac Surgery Atrial Fibrillation
NCT03702582Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Postoperative Length of Stay at 6 months. Started Apr 2019; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03702582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702582.